HR Execs on the Move

Genzyme

www.genzyme.com

 
Genzyme Corporation is a fully owned subsidiary of Sanofi. Before its acquisition in 2011, Genzyme was an American biotechnology company based in Cambridge, Massachusetts. In 2010, Genzyme was the world`s third-largest biotechnology company, employing more than 11,000 people around the world. As a subsidiary of Sanofi, Genzyme has a presence in approximately 40 countries, including 17 manufacturing facilities and 9 genetic-testing laboratories, its products are sold in 90 countries. In 2007, Genzyme generated $3.8 billion in revenues with more than 25 products in the market. In 2006 and 2007 Genzyme was named one of Fortune Magazine`s “100 Best Companies to ...
  • Number of Employees: 50K-100K
  • Annual Revenue: > $1 Billion
  • www.genzyme.com
  • 500 Kendall Street
    Cambridge, MA USA 08807
  • Phone: 908.981.5000

Executives

Name Title Contact Details
Michael O'Callaghan
VP of R&D Profile
Tom Scholl
VP R&D Profile
Karen Bissonnette
Manager CMO QA Profile
Priscilla Lim
Senior Director - Human Resources - Japan - Asia Pacific Profile
Michelle Smith
Senior Director Human Resource, Genzyme R&D, Global Medical Affairs Profile

Similar Companies

International Society for Biomedical Research on Alcoholism

International Society for Biomedical Research on Alcoholism is a Denver, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

DocComply

DocComply is a Cedar Grove, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Organ Recovery Systems

Organ Recovery Systems is a Des Plaines, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

GPO Plus

Headquartered in Las Vegas, Nevada, GPO Plus, Inc. (OTC: $GPOX) is a publicly traded global holding company of industry-specific Group Purchasing Organizations (GPO). The main holdings are HealthGPO, a Group Purchasing Organization for the Healthcare industry, and cbdGPO, a Group Purchasing Organization for the CBD and Hemp industry.

Voyager Therapeutics

Voyager Therapeutics is developing life-changing gene therapies from discovery, preclinical and clinical development, through to commercialization. We focus on people living with severe neurological diseases that lack safe and effective treatment options, particularly in the areas of Parkinson`s disease, monogenic forms of amyotrophic lateral sclerosis (ALS), Friedreich`s ataxia, Huntington`s disease, Alzheimer`s Disease and other tau-related neurodegenerative diseases, and severe, chronic pain. We are also committed to advancing the field of AAV (adeno-associated virus) gene therapy through innovation and investment in vector engineering and optimization, dosing techniques, as well as process development and production. Our management team and founders represent some of the most esteemed scientific and clinical leaders in the fields of AAV gene therapy, expressed RNA interference, neuroscience preclinical and clinical development, and manufacturing. We have broad strategic collaborations with Genzyme, a Sanofi company, AbbVie and the University of Massachusetts Medical School (UMMS). We have also entered into license and other agreements with UMMS, the University of California San Francisco and Stanford University to access relevant technology and data.